cambridge's bluebird bio licenses delivery tech to novartis, gsk
. © telegraph media group limited 2018
.
.
.it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
.
© telegraph media group limited 2018
it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done. .